Clinical-stage company led by world-class team targeting core neurotransmission pathways underlying neuropsychiatric disorders with a rich pipeline of ...
Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on devel...
ADCs are no longer a niche modality. To date, there are over a dozen approved ADCs on the market, and more than 500 programs are in clinical development, d...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety update regarding ELEVIDYS (...
Genmab A/S announced new results from the Phase 1b/2 EPCORE® NHL-2 trial Arm 10 (NCT04663347), evaluating epcoritamab, a T-cell engaging bispeci...
QIAGEN N.V. and Incyte announced a new global collaboration to develop a novel diagnostic panel to support Incyte’s extensive portfolio...
Collaboration will leverage Key2Brain’s technology to develop blood-brain barrier-crossing enzyme replacement therapies for lysosomal storage disor...
Persica Pharmaceuticals Limited (Persica), a clinical stage biotechnology company developing a transformative treatment for chronic Low Back Pain (cLBP),...
XL-protein GmbH, a pioneer in the area of biopolymers for pharmacokinetic optimization, announced that it has entered into a worldwide License, Dev...
SynaptixBio, the only company licensed to commercialise a treatment for a rare, deadly disease, says the drug could halt disease progression and even rever...
OBI Pharma, Inc. (OBI), a clinical-stage global oncology company specialized in the development of novel cancer therapies such as antibody-drug conjugate...
-SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Ther...
Samsung Bioepis Co., Ltd. (“Samsung Bioepis”) announced that the company has entered into a license, development and commercialization agreem...
Third asset to advance into clinical trials, validating broad potential of Launch-iT platform All subjects treated with first dose of AVX70371 Launch-...
© 2025 Biopharma Boardroom. All Rights Reserved.
